Statera BioPharma
Statera BioPharma is a Fort Collins, Colorado-based biopharmaceutical company developing a proprietary TLR5 agonist immunotherapy platform, with its lead asset Entolimod™ licensed exclusively to Tivic Health Systems for acute radiation syndrome treatment.
- Company typePrivate
- Founded2014
- HeadquartersFort Collins, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Statera BioPharma does
Statera BioPharma is a Fort Collins, Colorado-based biopharmaceutical research company founded in 2014, operating with a small team of 11–50 employees. The company is focused on immune health and immunotherapy, with its core technology centered on a proprietary TLR5 agonist platform. Its primary asset is Entolimod™, a late-stage TLR5 agonist therapeutic candidate developed to treat acute radiation syndrome — a medical countermeasure indication with primary relevance to U.S. Government and defense procurement scenarios.
The company's business model is asset-light and licensing-based rather than commercial-direct. In 2024, Statera granted Tivic Health Systems an exclusive global license to develop and commercialize Entolimod™ for acute radiation syndrome. Under this arrangement, Statera generates revenue (or has the potential to generate revenue) through licensing milestones and royalties, while its partner assumes the capital and execution burden of late-stage clinical development, regulatory approval, and commercialization.
The company's operating posture as of the most recent available signals is constrained: its own website displays only a WordPress "Coming Soon" page, suggesting minimal direct commercial operations or marketing activity. Total disclosed equity capital raised is approximately $26.1 million across two 2015 funding rounds, with no subsequent raises documented in the available sources. Leadership is led by CEO/President Mike Handley, supported by CFO Peter Aronstam and COO Taunia Markvicka. The company's strategic posture is best characterized as a single-asset licensor relying on a partner to realize the value of its proprietary TLR5 agonist platform in a niche government/defense health indication.
Statera BioPharma firmographics
Firmographics- Name
- Statera BioPharma
- Legal name
- Statera Biopharma
- Website
- https://staterabiopharma.com
- Company type
- Private
- Founded year
- 2014
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Statera BioPharma is a Fort Collins, Colorado-based biopharmaceutical company developing a proprietary TLR5 agonist immunotherapy platform, with its lead asset Entolimod™ licensed exclusively to Tivic Health Systems for acute radiation syndrome treatment.
- Ownership category
- akta.pro rank
Statera BioPharma industry classification
Industry- Product category
- Biopharmaceutical Therapeutics
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Transplantation & Advanced Therapies Pharmaceuticals (incl. Cell & Gene Therapies) (HLAIAAAO)
Keywords
Where Statera BioPharma is headquartered
LocationHeadquarters
- HQ city
- Fort Collins
- HQ country
- United States
- HQ region
- North America
Markets served
Statera BioPharma business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel
Revenue model
- Licensing and Royalty Revenue: Statera Biopharma generates revenue through exclusive licensing of its Entolimod platform technology to partners such as Tivic Health Systems, including potential milestone payments and ongoing royalties.
Statera BioPharma product offering
Product offeringCore offering
Statera BioPharma is a biopharmaceutical company developing immunotherapy therapeutics centered on its proprietary TLR5 agonist platform. Its primary asset, Entolimod, is a late-stage therapeutic candidate intended to treat acute radiation syndrome. The company has out-licensed Entolimod exclusively to Tivic Health Systems for global development and commercialization, generating licensing and royalty revenue.
Product overview
Statera Biopharma is a biopharmaceutical company focused on immune health and immunotherapy. The company's primary asset is Entolimod, a late-stage TLR5 agonist. Statera has exclusively licensed Entolimod to Tivic Health Systems (now operating as Tivic Biopharma) for global development and commercialization, while retaining certain rights as reflected in the licensing arrangement.
Differentiator
Problem solved
Functional benefit
Products and services
- Entolimod
Companies that use Statera BioPharma
Customer profileSegments1 record
Ideal customer profiles2 records
Statera BioPharma technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
Statera BioPharma partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Tivic Health SystemscoreStatera Biopharma granted Tivic Health Systems an exclusive license for the late-stage TLR5 agonist Entolimod™ to treat acute radiation syndrome. This represents a strategic licensing partnership where Statera out-licenses its proprietary immunotherapy technology to a partner focused on biopharmaceutical development and commercialization.
Recent moves4 records
Expansion highlights3 records
Statera BioPharma competitors and assessment
Company assessmentBroad incumbents
- Pfizer: Global biopharmaceutical company with a significant biodefense and infectious disease portfolio, including radiation-related countermeasure interests. Comparable as a broad incumbent with adjacent government/defense biopharma exposure.
- Merck & Co. Major biopharmaceutical company with a leading immunotherapy portfolio (e.g., Keytruda). Comparable as a broad incumbent shaping the immunotherapy market category in which Statera's TLR5 platform participates.
- Bristol Myers Squibb: Global biopharmaceutical leader with broad immunotherapy and immune-modulation franchises. Comparable as a large incumbent operating in the broader immune-health space Statera targets.
Emerging players
- Aeolus Pharmaceuticals: Clinical-stage company developing catalytic antioxidant compounds as medical countermeasures for radiation exposure. Comparable as a niche biodefense-focused biopharma targeting government procurement channels.
- AIM ImmunoTech: Clinical-stage immunotherapy company developing TLR3 agonist (Ampligen) and related immune-modulating therapeutics. Comparable through shared TLR-agonist immunotherapy platform technology and small-cap biopharma profile.
Regional players
- Eagle Pharmaceuticals: Specialty biopharmaceutical company focused on hospital and injectable therapies in the U.S. market. Comparable as a small-cap U.S.-based biopharma with a lean operating model and niche therapeutic focus.
Direct peers
- Humanetics Corporation: Developer of radioprotectant drugs for acute radiation syndrome and cancer therapy side effects. Closely comparable given its focus on TLR- and small-molecule-based radiation countermeasures for government and oncology markets.
- Soligenix: Late-stage biopharmaceutical company developing therapeutics for biodefense and rare diseases, including radiation countermeasures. Directly comparable as a small biopharma developing government-procured medical countermeasures with a focused pipeline.
- Tivic Health Systems: Strategic licensee of Statera's Entolimod platform and operator of biopharma operations around the TLR5 asset. Directly comparable as a party commercially advancing the same compound for the same indication.
Others
- Plurilock Security: Listed in the candidate set but operates in cybersecurity — included only as a contextual reference point and not a directly comparable biopharma peer.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat2 records
Key risks6 records
Key highlights5 records
Customer concentration
Statera BioPharma social profiles
Digital presenceStatera BioPharma financial estimates
Financial estimateRevenue estimate
Valuation estimate
Statera BioPharma leadership team
Management profileNumber of profiles
Profiles3 records
Statera BioPharma funding detail
Funding detailFunding overview
Funding rounds2 records
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Statera BioPharma M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Statera BioPharma
What does Statera BioPharma do?
Statera BioPharma is a biopharmaceutical company developing immunotherapy therapeutics centered on its proprietary TLR5 agonist platform. Its primary asset, Entolimod, is a late-stage therapeutic candidate intended to treat acute radiation syndrome. The company has out-licensed Entolimod exclusively to Tivic Health Systems for global development and commercialization, generating licensing and royalty revenue.
When was Statera BioPharma founded?
Statera BioPharma was founded in 2014. It employs 11 to 50 people.
Where is Statera BioPharma based?
Statera BioPharma is headquartered in Fort Collins, United States, in the North America region.
How does Statera BioPharma make money?
One revenue line is on record: licensing and Royalty Revenue.
Who are Statera BioPharma's main competitors?
Broad incumbents on record are Pfizer, Merck & Co. and Bristol Myers Squibb. Emerging players are Aeolus Pharmaceuticals and AIM ImmunoTech. Eagle Pharmaceuticals is listed as a regional player. Direct peers are Humanetics Corporation, Soligenix and Tivic Health Systems. Plurilock Security is listed as an others.
Does Statera BioPharma have an API?
No public API is recorded for Statera BioPharma.
What industry is Statera BioPharma in?
Statera BioPharma's product category is Biopharmaceutical Therapeutics. Its primary akta.pro industry code is HLAIAAAO, Transplantation & Advanced Therapies Pharmaceuticals (incl. Cell & Gene Therapies). Its NAICS code is 325414 and its SIC code is 2834.